KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Capital Expenditures (2016 - 2025)

Travere Therapeutics' Capital Expenditures history spans 13 years, with the latest figure at $140000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $140000.0; the TTM value through Sep 2025 reached $222000.0, up 107.48%, while the annual FY2023 figure was $668000.0, 249.74% up from the prior year.
  • Capital Expenditures reached $140000.0 in Q3 2025 per TVTX's latest filing, up from $82000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4.5 million in Q1 2021 to a low of $3000.0 in Q2 2023.
  • Average Capital Expenditures over 5 years is $441571.4, with a median of $92500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: tumbled 97.09% in 2022, then skyrocketed 2633.33% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $154000.0 in 2021, then tumbled by 80.52% to $30000.0 in 2022, then decreased by 16.67% to $25000.0 in 2023, then skyrocketed by 228.0% to $82000.0 in 2024, then surged by 70.73% to $140000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Capital Expenditures are $140000.0 (Q3 2025), $82000.0 (Q2 2024), and $25000.0 (Q4 2023).